Top Markets
Coin of the day
Kinnate Biopharma Inc. Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE
Rang in aandelen #21072
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily... Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.
Aandeelprijs
$2.65
Laatst gesynchroniseerd: 2024-04-03
Marktkapitalisatie
$115.71M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Kinnate Biopharma Inc. (KNTE)

Categorie

Koersgeschiedenis voor Kinnate Biopharma Inc. (KNTE)
Hoogste slotkoers: $2.65 op 2024-04-01

Laagste slotkoers: $40.13 op 2020-12-01
Koersgeschiedenis van Kinnate Biopharma Inc. van 2020 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2024 15.54%
2023 -63.61%
2022 -64.96%
2021 -55.12%
2020 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH